- Autores: Azzali Elisa, Coelho Tatiane, Costa Sofia Santos, Couto Isabel, da Silva Pedro Eduardo Almeida, Lopes Elizeth, Machado Diana, Pieroni Marco, Viveiros Miguel
- Ano de Publicação: 2016
- Journal: ASSAY and Drug Development Technologies
- Link: http://online.liebertpub.com/doi/abs/10.1089/adt.2016.752
Infections caused by Mycobacterium tuberculosis and other mycobacteria are major challenges for global public health. Particularly worrisome are infections caused by multidrug-resistant bacteria, which are increasingly difficult to treat because of the loss of efficacy of the current antibacterial agents, a problem that continues to escalate worldwide. There has been a limited interest and investment on the development of new antibacterial agents in the past decades. This has led to the current situation, in which there is an urgent demand for innovative therapeutic alternatives to fight infections caused by multidrug-resistant pathogens, such as multidrug-resistant tuberculosis.